The KRAS G12C inhibitor MK-1084 for <i>KRAS</i> G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.
Bibliographic record
Abstract
3508 Background: Preliminary data from the phase 1 KANDLELIT-001 trial (NCT05067283) showed a manageable safety profile and preliminary antitumor activity for MK-1084, a next-generation, selective KRAS G12C-GDP covalent inhibitor, in participants (pts) with previously treated, KRAS G12C-mutant solid tumors, including non–small-cell lung cancer and CRC. Here, we report data for MK-1084 monotherapy, MK-1084 + cetuximab, and MK-1084 + cetuximab + mFOLFOX6 in pts with advanced KRAS G12C-mutant CRC. Methods: KANDLELIT-001 enrolled pts with confirmed KRAS G12C mutation, RECIST-measurable disease, and ECOG PS 0-1. Pts with any advanced solid tumor and ≥1 prior systemic therapy received MK-1084 monotherapy PO QD or BID (total daily dose, 25-800 mg) in arms 1 and 3. Pts with advanced CRC and 1-2 prior systemic therapies received MK-1084 QD (total daily dose, 25-200 mg) plus cetuximab 500 mg/m 2 IV Q2W in arm 5. Pts with advanced CRC and 0-1 prior systemic therapies received MK-1084 QD (total daily dose, 25-100 mg) plus cetuximab 500 mg/m 2 Q2W and mFOLFOX6 in arm 6. The primary endpoints were dose-limiting toxicities (DLTs), AEs, and AEs leading to discontinuation. Secondary endpoints included ORR per RECIST v1.1 by investigator review. ORR was assessed in all pts who received their first MK-1084 dose ≥5 wk before the data cutoff date of August 12, 2024, for arms 1 and 3 and November 6, 2024, for arms 5 and 6. Results: In arms 1+3, 99 pts, including 53 (54%) with CRC, received MK-1084 alone. In arm 5, 34 pts, including 23 (68%) who had ≥2 prior lines of therapy, received MK-1084 + cetuximab. In arm 6, 20 pts, including 10 (50%) who had no prior therapy, received MK-1084 + cetuximab + mFOLFOX6. Median (range) study follow-up was 14.8 mo (0.2-30.8) in arms 1+3, 5.3 mo (2.6-11.5) in arm 5, and 1.9 mo (0.1-5.4) in arm 6. One pt in arm 6 experienced a DLT (grade 3 febrile neutropenia); there were no DLTs in arms 1, 3, or 5. Treatment-related AEs occurred in 62% of pts in arms 1+3, 97% of pts in arm 5, and 90% of pts in arm 6, were grade ≥3 in 9%, 18%, and 25%, respectively, and led to discontinuation of any drug in 1%, 3%, and 15%, respectively. There were no treatment-related deaths. The two most common treatment-related AEs in each arm were increased AST (17%) and nausea (17%) in arms 1+3, dermatitis acneiform (47%) and rash (24%) in arm 5, and nausea (55%) and rash (50%) in arm 6. ORR (95% CI) was 36% (23-50) in pts with CRC in arms 1+3 (n = 53), 50% (32-68) in arm 5 (n = 34), and 14% (2-43) in arm 6 (n = 14); all responses were partial responses. Conclusions: Preliminary data suggest that MK-1084 monotherapy, MK-1084 + cetuximab, and MK-1084 + cetuximab + mFOLFOX6 have manageable safety profiles and show evidence of antitumor activity in pts with advanced, KRAS G12C-mutated CRC. Pts continue to be followed, and enrollment continues. Clinical trial information: NCT05067283 .
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".